Bioceltix (WAR:BCX) Total Stockholders Equity: zł67.59 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BCX Bioceltix SA WAR:BCX
31 GF Score
Price zł80.00
! 1 Warning Sign
View Full Analysis

What is Bioceltix Total Stockholders Equity?

Bioceltix WAR:BCX 31 Total Stockholders Equity is zł67.59 Mil as of Mar. 2026. GuruFocus rates WAR:BCX with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Bioceltix's Total Stockholders Equity for the quarter that ended in Mar. 2026 was zł67.59 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Bioceltix's Book Value per Share for the quarter that ended in Mar. 2026 was zł12.22. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Bioceltix's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.00.

Bioceltix  (WAR:BCX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Bioceltix's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(67.591-0)/5.532
=12.22

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Bioceltix's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.171 + 0.064) / 67.591
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioceltix Total Stockholders Equity Related Terms

Bioceltix Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bioceltix's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioceltix Total Stockholders Equity Chart

Bioceltix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 6.00 5.15 10.47 38.78 73.28

Bioceltix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.62 31.39 27.00 73.28 67.59
WAR:BCX
31GF Score
Bioceltix SA WAR:BCX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of zł67.59 Mil mean?
Bioceltix (WAR:BCX) has a Total Stockholders Equity of zł67.59 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Bioceltix and its competitors.
Is Bioceltix's Total Stockholders Equity too high?
Bioceltix's current Total Stockholders Equity is zł67.59 Mil. Overall, Bioceltix has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Bioceltix's Total Stockholders Equity compare to VRTX and REGN?
Bioceltix's Total Stockholders Equity of zł67.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Bioceltix and its competitors. Bioceltix's current Total Stockholders Equity is zł67.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioceltix stock overvalued right now?
Bioceltix (WAR:BCX) has a current Total Stockholders Equity of zł67.59 Mil. The current Total Stockholders Equity is zł67.59 Mil. Bioceltix's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Bioceltix (WAR:BCX), the current Total Stockholders Equity is zł67.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioceltix Business Description

Address Bierutowska 57-59 Street, Wroclaw, POL, 51-317
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
31GF Score

Get the complete analysis for WAR:BCX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł80.00
Price